Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-02-08 | Compass Therapeutics, Inc. | Bisker-Leib Vered
(CHIEF EXECUTIVE OFFICER) |
F | Common Stock | D | 49198 | $1.45 - $1.45 | $71,337 |
2024-02-08 | Compass Therapeutics, Inc. | Schuetz Thomas J.
(PRESIDENT) |
F | Common Stock | D | 44782 | $1.45 - $1.45 | $64,933 |
2024-01-09 | Compass Therapeutics, Inc. | Bisker-Leib Vered
(Chief Executive Officer) |
A | Common Stock | A | 1753125 | $1.93 - $1.93 | $3,383,531 |
2024-01-09 | Compass Therapeutics, Inc. | Schuetz Thomas J.
(President of R&D) |
A | Common Stock | A | 637500 | $1.93 - $1.93 | $1,230,375 |
2023-11-17 | Compass Therapeutics, Inc. | Bisker-Leib Vered
(Chief Operating Officer) |
F | Common Stock | D | 64415 | $1.50 - $1.50 | $96,622 |
2023-11-17 | Compass Therapeutics, Inc. | Schuetz Thomas J.
(CHIEF EXECUTIVE OFFICER) |
F | Common Stock | D | 44025 | $1.50 - $1.50 | $66,037 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |